All In MedTech

Device Trial Radar · NCT07629557

Evaluate the Safety and Feasibility of Same-Day Bilateral Epithelium-On Corneal Cross-Linking for Keratoconus

Single-arm, Multi-center Study to Evaluate the Safety and Feasibility of Bilateral Epithelium-on Corneal Collagen Cross-linking With Epioxa™ HD/Epioxa™ and UV-A Irradiation Using the O2n™ System and Supplemental Oxygen Using the Boost Goggles® in Subjects With Keratoconus

Last checked: Nov 19, 2026Latest source record: Jun 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

May 11, 2026

Primary completion

Sep 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Glaukos CorporationPublic (GKOS)
Sponsor type
Industry
First posted
Jun 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 13 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Clinical trial to evaluate the safety and feasibility of corneal cross-linking in both eyes on the same day in subjects with keratoconus.

Conditions

  • Keratoconus

Interventions

  • Riboflavin Ophthalmic SolutionsDrug

    Riboflavin Ophthalmic Solutions

  • UV-A Irradiation SystemDevice

    O2n UV-A Irradiation System

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Successful completion of bilateral epithelium-on corneal collagen cross-linking.Time frame: Approximately 2.5 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Glaukos Investigative Site

    Westerville, Ohio · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.